July 16, 2004.
University of Utah,
Health Sciences Center.
The University of Utah's John A. Moran Eye Center has received a $100,000 grant from the Stephen A. and Elaine Wynn Charitable Foundation to fund continued research into retinal cell transplantation. The research is expected to help set the stage for human clinical trials of treatments for a blinding eye disease known as Retinitis Pigmentosa (RP).
The funding will support the work of Raymond D. Lund, Ph.D., the Calvin S. and Janeal N. Hatch Presidential Endowed Chair and Professor of Ophthalmology and Visual Sciences at the University of Utah. Groundbreaking research published by Lund's group in 2002 demonstrated that vision could be preserved in rats born with vision loss similar to the human disease Retinitis Pigmentosa by transplanting healthy cells from human biopsies into their eyes.
"Our initial research showed, in essence, that rats who would have been blind without a transplant were able to discriminate patterns as well as rats with normal vision. Our idea to transplant new cells into the eye to sustain and nurture defective cells is a novel approach that has proven successful beyond expectations," said Lund.
Before attempting this type of research in humans, however, Lund says there are more questions that need to be answered. Specifically, new research funded by the Wynn Foundation will evaluate whether any safety issues emerge, how late in the animal's life transplantation can be effective, and how to translate the laboratory experience to the clinic.
"Once we're satisfied that all of our questions are answered we'll begin planning for limited human clinical trials," said Lund. He emphasizes that the trials will include a very small number of RP patients.
According to the Foundation Fighting Blindness (www.blindness.org), patients with RP often experience a ring of vision loss in their mid-periphery with small islands of vision in their very far periphery. Other patients report the sensation of tunnel vision, as though they see the world through a straw. Many RP patients retain a small degree of central vision throughout their life.
Since the opening of the John A. Moran Eye Center in 1993, the Stephen A. and Elaine Wynn Charitable Foundation has provided the center with nearly $500,000 in funding through grants. The Wynn family has also played an important role in fundraising for the center and Mr. Wynn sits on the center 's Advisory Board.
"The goal of the foundation is to provide seed money to scientists and programs whose research is nearing human clinical trials. We've been especially impressed with Dr. Lund and his team of scientists because of the great sensitivity they've shown to patients suffering from blinding eye diseases. Dr. Lund recognizes that for patients and their families this type of research is a race toward treatment," according to Steven Dezii, a foundation trustee and spokesperson.
About the John A. Moran Eye Center: Named after University of Utah alumnus and New York financier John A. Moran, the center is the largest vision treatment and research center between the west coast and Texas. The center's 42 faculty members and 300 staff include ophthalmologists, optometrists, and basic science vision researchers from 10 different countries. The center's basic science research is focused on the areas of artificial vision, ophthalmic genetics and genetic therapies, retinal cell regeneration and transplantation, and greater understanding of the retina and retinal cell development. Construction is currently underway on a new $53 million 200,000 square foot center that will provide additional space for both clinical and basic science research.
More information: www.hsc.utah.edu.
End of article.
Any further reproduction or distribution of this article in a format other than a specialized format is an infringement of copyright.
Go to ...
Top of Page.
List of Categories.
Blind World Website
Designed and Maintained by:
All Rights Reserved.